BACKGROUND: Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC). METHODS: Oral everolimus and gefitinib were both administered daily to patients with progressive NSCLC. Patients were enrolled in 3-patient cohorts at everolimus dose levels of 5 and 10 mg daily. All patients received gefitinib 250 mg daily. RESULTS: Ten patients were enrolled. The maximum tolerated dose of everolimus was 5 mg when administered daily with gefitinib 250 mg. Two patients who were treated at the 10 mg dose level of everolimus experienced dose-limiting toxicity, including grade 5 hypotension and grade 3 stomatitis. Pharmacokinetic studies demonstrated no consistent, significant interaction on the t(max), C(max), and AUC(0-8h) of either agent. Two partial radiographic responses were identified among the 8 response-evaluable patients. CONCLUSIONS: For further study, everolimus at a dose of 5 mg daily in combination with daily gefitinib 250 mg is recommended. The 2 radiographic responses identified are encouraging. A phase 2 trial in patients with NSCLC is under way. (c) 2007 American Cancer Society.
BACKGROUND: Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC). METHODS: Oral everolimus and gefitinib were both administered daily to patients with progressive NSCLC. Patients were enrolled in 3-patient cohorts at everolimus dose levels of 5 and 10 mg daily. All patients received gefitinib 250 mg daily. RESULTS: Ten patients were enrolled. The maximum tolerated dose of everolimus was 5 mg when administered daily with gefitinib 250 mg. Two patients who were treated at the 10 mg dose level of everolimus experienced dose-limiting toxicity, including grade 5 hypotension and grade 3 stomatitis. Pharmacokinetic studies demonstrated no consistent, significant interaction on the t(max), C(max), and AUC(0-8h) of either agent. Two partial radiographic responses were identified among the 8 response-evaluable patients. CONCLUSIONS: For further study, everolimus at a dose of 5 mg daily in combination with daily gefitinib 250 mg is recommended. The 2 radiographic responses identified are encouraging. A phase 2 trial in patients with NSCLC is under way. (c) 2007 American Cancer Society.
Authors: Karen E Bullock; William P Petros; Islam Younis; Hope E Uronis; Michael A Morse; Gerard C Blobe; S Yousuf Zafar; Jon P Gockerman; Joanne J Lager; Roxanne Truax; Kellen L Meadows; Leigh A Howard; Margot M O'Neill; Gloria Broadwater; Herbert I Hurwitz; Johanna C Bendell Journal: Cancer Chemother Pharmacol Date: 2010-11-16 Impact factor: 3.333
Authors: Katharine A Price; Christopher G Azzoli; Lee M Krug; Maria C Pietanza; Naiyer A Rizvi; William Pao; Mark G Kris; Gregory J Riely; Robert T Heelan; Maria E Arcila; Vincent A Miller Journal: J Thorac Oncol Date: 2010-10 Impact factor: 15.609
Authors: Ramon Andrade De Mello; Pedro Nazareth Aguiar; Hakaru Tadokoro; Tállita Meciany Farias-Vieira; Pedro Castelo-Branco; Gilberto de Lima Lopes; Daniel Humberto Pozza Journal: J Thorac Dis Date: 2018-06 Impact factor: 2.895
Authors: Matias Casás-Selves; Jihye Kim; Zhiyong Zhang; Barbara A Helfrich; Dexiang Gao; Christopher C Porter; Hannah A Scarborough; Paul A Bunn; Daniel C Chan; Aik Choon Tan; James DeGregori Journal: Cancer Res Date: 2012-06-27 Impact factor: 12.701
Authors: M-C Liang; J Ma; L Chen; P Kozlowski; W Qin; D Li; J Goto; T Shimamura; D N Hayes; M Meyerson; D J Kwiatkowski; K-K Wong Journal: Oncogene Date: 2009-12-07 Impact factor: 9.867